GlassScriptPhysician profile
Rachel W Winter
NPI 1730492216
$47,182.27
in general payments reported to CMS, 2019-2025
8 companies · $3,790 in 2025
The $3,790 reported for 2025 was more than what 89% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18.08 · 2021: $3,450 · 2022: $8,284 · 2023: $30K · 2024: $1,897 · 2025: $3,790.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $29K · Consulting Fee: $5,669 · Travel and Lodging: $302 · Food and Beverage: $298 · Education: $30.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $29,130.51 |
| Consulting Fee | $5,668.75 |
| Travel and Lodging | $302.02 |
| Food and Beverage | $298.26 |
| Education | $30.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $29,278.04 | 2022-2024 | |
| E.R. Squibb & Sons, L.L.C. | $8,980.24 | 2022-2023 | |
| Abbvie INC. | $4,144.60 | 2021-2025 | |
| Celltrion USA INC. | $3,177.39 | 2025 | Zymfentra |
| Celgene Corporation | $1,407.50 | 2022 | |
| Boston Scientific Corporation | $87.04 | 2023-2025 | Captivator II, Resolution 360 Clip |
| Takeda Pharmaceuticals U.S.A., INC. | $77.06 | 2019-2022 | |
| Pfizer INC. | $30.40 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Winter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.